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Mutations in the diastrophic dysplasia sulfate transporter (DTDST or SLC26A2) cause a family of recessively
inherited chondrodysplasias including, in order of decreasing severity, achondrogenesis 1B, atelosteogen-
esis 2, diastrophic dysplasia (DTD) and recessive multiple epiphyseal dysplasia. The gene encodes a
widely distributed sulfate/chloride antiporter of the cell membrane whose function is crucial for the uptake
of inorganic sulfate, which is needed for proteoglycan sulfation. To provide new insights in the pathogenetic
mechanisms leading to skeletal and connective tissue dysplasia and to obtain an in vivo model for thera-
peutic approaches to DTD, we generated a Dtdst knock-in mouse with a partial loss of function of the sulfate
transporter. In addition, the intronic neomycine cassette in the mutant allele contributed to the hypomorphic
phenotype by inducing abnormal splicing. Homozygous mutant mice were characterized by growth retar-
dation, skeletal dysplasia and joint contractures, thereby recapitulating essential aspects of the DTD pheno-
type in man. The skeletal phenotype included reduced toluidine blue staining of cartilage, chondrocytes of
irregular size, delay in the formation of the secondary ossification center and osteoporosis of long bones.
Impaired sulfate uptake was demonstrated in chondrocytes, osteoblasts and fibroblasts. In spite of the gene-
ralized nature of the sulfate uptake defect, significant proteoglycan undersulfation was detected only in
cartilage. Chondrocyte proliferation and apoptosis studies suggested that reduced proliferation and/or
lack of terminal chondrocyte differentiation might contribute to reduced bone growth. The similarity with
human DTD makes this mouse strain a useful model to explore pathogenetic and therapeutic aspects of
DTDST-related disorders.
INTRODUCTION
Proteoglycans are a family of macromolecules characterized
by one or more glycosaminoglycan (GAG) chains covalently
linked to a core protein. They are present predominantly in
the extracellular matrix or associated with the cell surface of
eukaryotic cells, where they bind to other matrix and cell-
associated components and to growth factors. Their specific
functions derive from the chemical and structural diversity
of either (or both) the polysaccharide or core protein part.
The importance of proteoglycans as constituents of the extra-
cellular matrix and of the cell surface is demonstrated by
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differential expression during development and by disorders
caused by mutations in genes encoding the core proteins or
specific enzymes involved in their metabolism in human and
animal models. GAGs are composed of characteristic repeat-
ing disaccharide units with sulfate groups at various positions
and in different combinations. Sulfate groups attached to
specific positions play important roles in the formation of
biologically active domain structures and contribute to the
high polyanionic charge of proteoglycans (1).
Sulfate groups are transferred from 30-phosphoadenosine
50-phosphosulfate (PAPS) to macromolecules by specific
sulfotransferases. PAPS, the high-energy sulfate donor for
macromolecular sulfation, is synthesized from cytoplasmic
sulfate by PAPS synthase, a bifunctional enzyme with ATP-
sulfurylase activity and adenosine 50-phosphosulfate kinase
activity (2). Intracellular sulfate comes either from the extra-
cellular space or, to a lesser extent, from the intracellular cata-
bolism of thiols (i.e. cysteine or methionine); the contribution
of the two pathways to the intracellular sulfate pool depends
on the cell type (3–7).
Owing to its anionic charge, extracellular sulfate is trans-
ported into the cytoplasm by specific anion transporters. The
protein responsible for this transport appears to be the dia-
strophic dysplasia sulfate transporter (DTDST, also known
as SLC26A2); the isolation of the gene coding for this
sulfate/chloride antiporter of the cell membrane was the
result of a long-term project aimed at elucidating the molecu-
lar basis of diastrophic dysplasia (DTD), a recessive skeletal
dysplasia particularly frequent in the Finnish population (8),
but present worldwide (9). Other sulfate transporters have
been recently identified: SLC26A1, SLC26A3, SLC26A4
(previously known as SAT-1, CLD or DRA and PDS, respect-
ively) and SLC26A5–A9 (10–17). Their expression is limited
to specific tissues, suggesting that they play specific anion
transport activities. On the contrary, DTDST is expressed in
many tissues (8); however, the main phenotypic consequences
of its functional impairment are restricted to bone and joints
(18).
Mutations in the DTDST gene are associated with a family
of recessively inherited chondrodysplasias including, in order
of increasing severity, a recessive form of multiple epiphyseal
dysplasia (rMED) (19), DTD (8), atelosteogenesis type 2 (20)
and achondrogenesis 1B (21). Achondrogenesis 1B and
atelosteogenesis type 2 are lethal before or shortly after
birth; patients with DTD survive with major physical impair-
ments, whereas the clinical phenotype in rMED is relatively
mild (22). The mutations identified so far in DTDST chondro-
dysplasias include single amino acid substitutions or deletions,
premature stop codons and reduced mRNA levels caused by
splice-site mutations (9).
The main biochemical consequence of reduced intracellular
sulfate levels caused by sulfate transport impairment is carti-
lage proteoglycan undersulfation. Thus, cartilage from
DTDST patients has a reduced total sulfate content (21), con-
tains undersulfated GAGs as shown by chondroitin sulfate
disaccharide analysis and stains poorly with toluidine blue
or alcian blue (23–25). On the basis of clinical, molecular
and biochemical studies performed so far, a correlation has
been traced between the different clinical phenotypes, the
nature of the mutation in the DTDST, the residual activity
of the sulfate transporter and cartilage proteoglycan undersul-
fation (23). Although DTDST is widely expressed, sulfation
has not been measured in tissues other than cartilage.
However, the presence of severe contractures in DTD patients
suggests involvement of other connective tissues.
The importance of proteoglycan sulfation in skeletal devel-
opment is also illustrated by a distinct, recessive form of spon-
dyloepimetaphyseal dysplasia described in a large Pakistani
family (SEMD Pakistani type) (26) and by its homologous
murine model, the brachymorphic (bm ) mouse (27); both con-
ditions are caused by missense mutations in PAPS synthase 2
leading to a reduced function of the enzyme and thus reduced
PAPS level. Cartilage proteoglycan undersulfation has been
demonstrated in the animal model (28), whereas proteoglycan
sulfation studies were not possible in SEMD Pakistani type
patients.
The major involvement of cartilage in the human pheno-
types of DTDST disorders, in SEMD Pakistani type and in
the bm mouse demonstrates the crucial role of sulfate acti-
vation in the maturation of cartilage extracellular matrix
macromolecules and the consequences of defects in this
pathway on the architecture, composition and mechanical
properties of cartilage as well as on the skeletogenesis.
However, a detailed picture of the molecular and cellular
events that could account for the specific defects in cartilage
and bone matrix resulting in dwarfism, progressive joint
disease and malformed skeleton is far from complete. To
provide new insight on the role of proteoglycan sulfation in
the development and homeostasis of the skeleton, we have
generated the first mouse strain with a mutation in the Dtdst
gene causing a partial loss of function of the sulfate transpor-
ter. We show that the mutation introduced in the murine Dtdst
locus results in a skeletal and connective tissue phenotype,
which reproduces at the clinical, morphological and biochemi-
cal level the human DTDST chondrodysplasias.
RESULTS
Generation of the Dtdst mutant mice
Transgenic mice harboring an A386V substitution in the
eighth transmembrane domain of the DTDST were generated
by homologous recombination in embryonic stem cells. To
knock-in the A386V substitution, a C1184T transition was
introduced by site-directed mutagenesis in a cloned fragment
of exon 3. This mutation was detected in the homozygous
state in a patient with a non-lethal form of DTD characterized
by short stature, cleft palate, deformity of the external ear
and ‘hitchhiker’ thumb deformity (9). A knock-out was consi-
dered unsuitable, because a total loss of function might result
in lethality during the fetal period as observed in achondro-
genesis 1B, the most severe condition in DTDST chondrodys-
plasias in humans.
A gene targeting vector was designed to knock-in the C.T
transition in the murine Dtdst gene; for this purpose, the
mouse Dtdst gene was isolated from a 129Sv/J mouse
genomic bacterial artificial chromosome (BAC) library by
polymerized chain reaction (PCR) screening using primers
specific for exons 2 and 3. Both exons, which contain the
whole coding sequence of the Dtdst, separated by an intron
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of 1.8 kb as in the human homolog were identified in two
clones. The genomic locus of the murine Dtdst was targeted
with a replacement vector containing 8.3 kb of DNA sequence
interrupted in intron 2 by the neomycin (neo) resistance
cassette, driven by the phosphoglycerate kinase (PGK) promo-
ter, for positive selection. For negative selection of non-
homologous recombinants, the herpes simplex thymidine
kinase was used, driven by the polyoma virus thymidine kinase
(MC1) promoter (Fig. 1A). Embryonic stem clones that had
undergone homologous recombination were identified by
Southern blot analysis using two probes for the 50 and 30
end (Fig. 1B) of the targeted region. The 50 end probe detected
a 7.9 kb BstX-I fragment specific for the targeting allele and a
6.2 kb fragment for the wild-type allele; the 30 end probe
detected a 6.4 kb Bsu36-I fragment for the targeted allele
and a 4.7 kb fragment for the wild-type allele. Two indepen-
dent embryonic stem clones with an euploid karyotype were
used to produce male chimeras; germline transmission of the
targeted allele was achieved for both clones when bred to
C57Bl/6J females. As expected, no apparent defects were
observed in heterozygous animals. By mating heterozygous
animals, homozygous mice were born in the expected Mende-
lian segregation ratio.
In the targeted allele, the neo gene was present in intron 2 at
a HindIII site 174 bp upstream of the 30 end of the intron, thus
making the intron itself approximately twice as large as the
wild-type. The consensus sequence for the branch site lies
22 nt upstream of the 30 splice junction. To test whether the
neo gene interfered with correct splicing, we studied the
expression of the Dtdst by northern blotting of mRNA purified
from skin (Fig. 1C). The expected 8 kb transcript was detected
in the wild-type and, to a lesser extent, in hetero- and homo-
zygous animals; both in hetero- and homozygous mutant
animals, an additional band with a higher molecular weight
was identified. This indicated that splicing of exon 2 onto
exon 3 was impaired, most likely as a consequence of the
neo gene within the intron. These data were confirmed by
probing the northern blot with a neo probe, which hybridized
only to the abnormal band (data not shown). The abnormal
band was 40 and 60% of the total Dtdst transcript in
hetero- and homozygous mutant animals, respectively. The
total Dtdst transcript relative to glyceraldehyde 3-phosphate
dehydrogenase was normal indicating that the presence of
the neo gene do not interfere with mRNA degradation.
Thus, in this mouse strain, functional impairment of the
Dtdst was due not only to the knocked-in missense mutation,
but also to a reduced level of correctly spliced transcript. In
spite of the dual pathogenetic mechanism, the interesting phe-
notype of this first strain justified a detailed characterization.
Phenotypic characterization of mutant mice
Mice heterozygous for the Dtdst mutation did not show any
phenotypic changes, as is the case for carriers of DTDST
mutations; body weight was normal, and no skeletal defects
were observed by double staining with alcian blue and alizarin
red of the skeleton (data not shown). All subsequent studies at
the biochemical level failed to uncover any manifestation of
heterozygosity: proteoglycan sulfation in cartilage, bone and
skin were within normal values (data not shown), as well as
sulfate uptake assay in chondrocytes (Fig. 6).
Homozygous animals were obtained by mating heterozy-
gous mice. The phenotype of the offspring was observed
from birth to 2 months of age by visual inspection; in addition,
Figure 1. Gene targeting strategy of the Dtdst locus. (A) Schematic represen-
tation of the Dtdst locus, gene targeting vector and recombination at the Dtdst
locus. The protein coding region of the Dtdst is distributed in exons 2 and 3.
The gene targeting vector carrying the C.T transition (M) in exon 3 and a
neomycin (neo) gene flanked by loxP sequences in intron 2 was electro-
porated in mouse embryonic stem cells. The targeted allele was obtained by
homologous recombination between the gene targeting vector and a wild-
type Dtdst allele. (B) Southern blot analysis of DNA from embryonic stem
clones. The 7.9 kb BstX I fragment and the 6.4 kb Bsu36 I fragment indicate
proper 50 and 30 targeting of the Dtdst locus. The 6.2 kb BstX I and 4.7 kb
Bsu36 I fragments are from the wild-type allele. (C) Northern blot analysis
of poly(A)þ RNA from skin of pups at P1 hybridized with a Dtdst and a
glyceraldehyde 3-phosphate dehydrogenase (G3PDH ) probe. A band
corresponding to the correctly spliced Dtdst transcript is detected in the
wild-type (þ/þ), and, to a lesser extent, in heterozygous (þ/2) and homo-
zygous (2/2) animals. Both in hetero-and homozygous animals, an additional
band (arrow) with a higher molecular weight is present indicating impaired
splicing of exon 2 onto exon 3 caused by the neo gene within the intron.
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skeletal development was studied by radiographic analysis and
by double staining with alcian blue and alizarin red. At birth,
mutant pups were alive and barely distinguishable from wild-
type and heterozygous littermates: they were slightly shorter
than wild-type littermates and the milk spot was smaller, indi-
cating reduced viability (Fig. 2A). However, during the first
days of life, mutant animals became easily identifiable
because their growth was reduced; in addition, at postnatal
day (P)14, thoracic kyphosis was observed at visual inspection.
The kyphosis became progressively more pronounced until P60,
when mutants had a characteristic posture with flexed head.
Body weight at birth was not significantly reduced when
compared with wild-type mice, but delayed growth resulted
in a reduction of 60% at age P60 (P , 0.0001) (Fig. 3).
Mortality of mutant animals was 50% from birth to P21.
Overall motor activity of mutants was reduced, and adult
animals had difficulties in climbing and hanging in the cage;
for this reason, pelleted food had to be deposited directly
onto the cage floor. Moreover, mutant animals sometimes
walked backward rather than forward, a phenomenon that
we interpreted as being related to pain or reduced mobility
at the ischio-femoral and knee joints. In fact, in mice, the
movement of hind leg joints are wider and potentially more
painful when walking forward than backward.
Skeletal studies were performed from P1 to P21 by staining
with alcian blue and alizarin red (Fig. 2B) and at P60 by
X-rays (Fig. 2C). At birth, bending of the tibia was present,
but no other skeletal abnormalities were observed. At P7,
mutant mice developed thoracic kyphosis, which became
progressively more severe at P14 and P21. In addition, mice
showed bite overclosure (overgrowth of the mandible relative
to the maxilla, resulting in lower incisors being placed ante-
riorly to upper incisors) and shortening of long bones. Ossifi-
cation of skeletal elements was normal, on the basis of skeletal
staining with alcian blue and alizarin red.
X-rays at P60 recapitulate the skeletal defects: shortening of
tubular bones, severe thoracic kyphosis and abnormal thoracic
cage with reduced volume, bite overclosure and hip dysplasia
with pelvic deformity (Fig. 2C). Most homozygous mutant
mice died before 6 months of age; on the basis of the clinical
data, the direct cause of death could be the respiratory
complications related to kyphosis, although we cannot
exclude neurological problems or malnutrition due to dental
malocclusion.
Histological studies of epiphyseal cartilage
Sections of the tibial and femoral epiphysis from animals from
P1 to P60 were stained with toluidine blue or with hematoxylin
and eosin (H&E). In patients with DTDST disorders (with the
exception of rMED), reduced staining of cartilage tissue sec-
tions with alcian blue or toluidine blue has been reported as a
consequence of proteoglycan undersulfation. In mutant
animals, cartilage matrix stained less intensely with toluidine
blue when compared with age-matched wild-type littermates;
in addition, some areas stained less than others with a patchy
appearance (Fig. 4A). In mutant animals, chondrocyte size
was more variable with many cells smaller than control ones.
We hypothesized that tubular bone shortening and reduced
growth might be produced by changes at the growth plate, and
we looked for this evidence in sections of the tibia. At P21, the
overall architecture of the growth plate was preserved, with
resting, proliferative and hypertrophic zones well defined.
Columnization was present, and the width of the proliferative
zone was not significantly different between mutant and
wild-type animals on inspection. Chondrocyte apoptosis was
evaluated in the growth plate by deoxynucleotidyltransfer-
ase-mediated dUTP-fluorescein nick end labeling (TUNEL)
assay (Fig. 4B). In the wild-type, TUNEL-positive chondro-
cytes were present in the hypertrophic zone; whereas in
mutant animals, cell death in the hypertrophic zone was
reduced, suggesting that in mutant chondrocytes, there may
be a delay in reaching the terminal differentiation that deter-
mines hypertrophy and death. A marked change in the growth
plate was observed at P60: at low magnification, the growth
plate appeared as a straight line in wild-type animals;
whereas in mutant animals, it was irregularly delineated and
in some regions appeared to be disrupted, with bony fusion
of the epiphysis to the metaphysis (Fig. 5A and C). At
higher magnification, few chondrocyte columns in the proli-
ferative zone were evident (Fig. 5C). At the same age, we
observed degeneration and fragmentation of articular cartilage
of the knee joints and hypertrophy of the sinovia. In addition
the long bones were osteoporotic: epiphyseal and metaphyseal
trabecular structures were thinner, fewer and poorly connected
to each other when compared with age-matched controls
(Fig. 5C).
The formation of the secondary ossification center of the
proximal epiphysis from the tibia was studied from P7 to
P21 by H&E staining (Fig. 5B). In mice, the epiphyses are
entirely cartilaginous at P1–P7; the formation of the second-
ary ossification center (P7–P14) initiates as a blood vessel
penetrates from the articular surface into the epiphysis (P4)
followed by differentiation of surrounding chondrocytes. In
mutant animals, the penetration of the blood vessel from the
articular surface seemed normal (data not shown). In the
wild-type, the second ossification center was well developed
at P14, whereas in mutant animals at the same age, its
formation was still at the beginning, suggesting a delay in
chondrocyte differentiation.
Chondrocyte proliferation studies
To determine whether reduced bone growth in mutant animals
was due to reduction in chondrocyte proliferation, we assessed
the percentage of cells undergoing de novo DNA synthesis by
5-bromo-2-deoxy-uridine (BrdU) incorporation into primary
chondrocyte cultures. For this purpose, cells were grown for 2
days, labeled with BrdU for the last 4 h of culture, and then
stained with a specific anti-BrdU antibody. In mutant chon-
drocytes, the percentage of cells incorporating BrdU was
significantly reduced compared with wild-type cells, sug-
gesting a reduced proliferation capacity in vitro (12 + 7 and
20 + 8%, respectively; P, 0.05).
Biochemical studies
The activity of the sulfate transporter was tested in fibroblasts
and in primary cultures of chondrocytes and osteoblasts.
Sulfate uptake assays were performed by pulse labeling
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Figure 2. The morphologic features of homozygous animals for the Dtdst mutant allele are very reminiscent of human DTD. (A) The mutant (2/2) P1 pups are
alive, slightly shorter than heterozygous (þ/2) or wild-type (þ/þ) littermates. The milk spot (arrows) is smaller, indicating reduced viability when compared
with heterozygous or wild-type animals. At visual inspection, a thoracic kyphosis is observed at P14 in mutant animals. Because of the kyphosis at P60, homo-
zygotes show a characteristic posture with flexed head. (B) alcian blue (cartilage) and alizarin red (bone) staining of the whole skeleton. The thoracic kyphosis
identified by visual inspection at P14 is already present at P7, causing deformity of the thoracic cage. In addition, mutant pups show bite overclosure and short-
ening of long bones. (C) X-rays at P60. In the mutant animal, shown at a higher magnification than the wild-type, shortening of tubular bones, severe thoracic
kyphosis, bite overclosure and hip dysplasia are observed. The skull and the pelvis are shown at higher magnification to illustrate bite overclosure and hip
dysplasia.
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with [35S]sulfate for 1 min in medium containing varying
concentrations of unlabeled sodium sulfate. In chondrocytes
and fibroblasts from homozygous animals, the uptake was
reduced at all sulfate concentrations tested when compared
with wild-type or heterozygous animals (Fig. 6). These data
validate our mouse model, because in patients with DTDST
chondrodysplasias, sulfate uptake impairment has been
observed in both cell types. Although it is known that the
sulfate transporter is expressed in osteoblasts (29), sulfate
uptake has never been studied in this cell type from patients
with DTDST disorders. The same assay performed in osteo-
blasts from mutant animals showed sulfate uptake impairment
suggesting that also in this cell type a large proportion of the
intracellular sulfate pool is probably mediated by Dtdst (Fig. 6).
Sulfation of proteoglycans was then studied in different
tissues of the mouse strain. It has been demonstrated (with
the exception of rMED) that cartilage chondroitin sulfate
proteoglycans are undersulfated in DTDST chondrodyspla-
sias; however, even if tissue abnormalities are restricted to
cartilage, no information is available regarding proteoglycan
sulfation in other tissues such as skin or bone where the
DTDST is expressed. For this reason, we measured proteogly-
can sulfation in cartilage, skin and bone from mutant and wild-
type animals. In addition, sulfation was measured at different
ages from P1 to P60 to trace the course of proteoglycan sulfa-
tion during post-embryonic development in wild-type and
mutant animals. Tissues were digested with papain to
remove proteins and proteoglycan core proteins; GAGs were
then recovered by cetylpyridinium chloride precipitation.
After hyaluronic acid removal, chondroitin sulfate GAGs
were digested with chondroitinase ABC and ACII, and
released disaccharides were quantitated by HPLC. The
degree of proteoglycan sulfation was measured as the
amount of non-sulfated disaccharide (DDi-0S) relative to
DDi-0S and mono-sulfated disaccharides (DDi-4S and DDi-
6S). HPLC separation of cartilage samples demonstrated
that in mutant animals, the relative amount of non-sulfated
disaccharide was higher when compared with wild-types, pro-
viding direct evidence of reduced chondroitin sulfate proteo-
glycan sulfation (Fig. 7). Interestingly, in mutant animals,
the highest values of proteoglycan undersulfation were
Figure 3. Body weight of mutant and wild-type mice from P1 to P60. The
body weight confirms delayed growth of mutant animals resulting in a
reduction of 60% at P60. The average values with the standard deviation
are shown for wild-type (wt) and mutant (dtd) animals (n ¼ 10–15 for each
age point; at P1, differences were not statistically significant; at the other
age points P, 0.05).
Figure 4. Decreased toluidine blue staining of cartilage from mutant animals
and TUNEL staining of the growth plate. (A) In mutant animals (dtd), the
cartilage matrix from the distal epiphysis of the femur is less intensely
stained with toluidine blue when compared with wild-type (wt) animals
with some areas staining less than other areas. In addition, chondrocytes are
smaller and their size is more variable when compared with wild-type litter-
mates. (B) Sections of the tibia of wild-type (wt) and mutant (dtd) animals
at P21 were analyzed for the presence of apoptotic chondrocytes in the
growth plate. In the wt apoptotic chondrocytes (green) were present in the
hypertrophic region, whereas in the dtd, low frequency of apoptotic chondro-
cytes was detected in the whole growth plate. h: hypertrophic zone; ph, pre-
hypertrophic zone; p, proliferating zone. Magnifications are 115 in (A)
and 140 in (B).
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observed at birth (32% of non-sulfated disaccharide versus
9.5% in controls, P , 0.0001), whereas proteoglycan sulfation
increased with age, even if not within normal values. Proteogly-
cans obtained from the femoral diaphysis of mutant animals
were slightly undersulfated and, as already observed in carti-
lage, sulfation increased with age (Fig. 7); unfortunately, we
have no data concerning bone proteoglycan sulfation in
mutant animals at P1 because of too small amount of bone
available for the analysis.
Chondroitin/dermatan sulfate disaccharide analysis of skin
frommutant animals showed that proteoglycan sulfationwas com-
parable to that of wild-type animals at all age points considered
(P1–P60) (Fig. 7), consistent with the lack of any phenotypic
alteration of skin in the mouse strain, as well as in DTD patients.
Figure 5. Structural alteration of the growth plate and delayed formation of the secondary ossification center. (A) H&E staining of the knees of animals, at P60.
In mutant animals, the growth plate is irregularly delineated, and in some regions, it is disrupted with bony fusion of the epiphysis to the metaphysis (see arrow in
A2 and magnification in C7). The areas enclosed in the boxes are shown at higher magnification in C1–2 and C5–6. (B) Formation of the secondary ossification
center of the proximal epiphysis from the tibia from P7 to P21 in wild-type (wt) and mutant animals (dtd). At P14, the secondary ossification center is well
developed in wt animals, but in the dtd, its formation is delayed suggesting a defect in chondrocyte differentiation. Sections are stained with H&E. (C) Enlarged
views of bone tissue (panels 1 and 2), growth plate (panels 3 and 4) and articular cartilage (panels 5 and 6) at P60. In bone tissue, trabecular structures are thinner
and poorly connected to each other when compared with age-matched controls (panels 1 and 2). Although less intense staining of matrix is evident, the sections
of the tibial growth plate do not show significant differences in growth plate architecture, except for a possible rarefaction of chondrocytes and few chondrocyte
columns in mutant animals (panels 3 and 4). Articular cartilage in mutant animals is degenerated and fragmented with sinovia hypertrophy (panels 5 and 6).
Magnifications are 10 in (A), 70 in (B), 85 in C1–2, 125 in C3–4, 65 in C5–6 and 60 in C7.
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DISCUSSION
We have set out to generate a mouse model for skeletal dys-
plasias caused by mutations in the Dtdst gene. The strategy
we designed consisted of knock-in of a single amino acid sub-
stitution that resulted in DTD of moderate severity in a human
patient. The choice of a mutation associated with moderate
severity in humans had been dictated by the aim of producing
an affected but viable mouse and by the chance of generating a
lethal phenotype during the perinatal period with a more
severe mutation. The first strain of mice we obtained
showed a phenotype that closely reproduced DTD, being
characterized by dwarfism, skeletal deformities and joint con-
tractures. Subsequent biochemical, histologic and radiographic
analyses confirmed functional inactivation of Dtdst, thus
Figure 6. Functional assay of the Dtdst in different cell lines. Chondrocytes
and osteoblasts in primary culture and skin fibroblasts from wild-type (wt)
and mutant animals (dtd) were analyzed for uptake of inorganic sulfate. In
the three cell lines considered, sulfate uptake is impaired in dtd animals,
demonstrating that the chondrodysplasia phenotype is caused by targeting of
the Dtdst. The activity of the sulfate transporter in the heterozygote (het) is
within normal values confirming the lack of any phenotypic change in these
animals. Sulfate uptake in chondrocytes was performed in two different
wild-type mice, as well as in two dtd.
Figure 7. Sulfation of chondroitin sulfate proteoglycans in cartilage, bone and
skin of animals at different ages from P1 to P60. The degree of proteoglycan
sulfation has been determined by HPLC, on the basis of the amount of
non-sulfated disaccharide (DDi-0S) relative to DDi-0S and mono-sulfated dis-
accharide (DDi-4S and DDi-6S). Analysis of cartilage from the femoral head
demonstrates that in mutant animals (dtd), the relative amount of non-sulfated
disaccharide is higher when compared with wild-type (wt) littermates, provid-
ing direct evidence of reduced chondroitin sulfate proteoglycan sulfation
(P, 0.05). Interestingly, in mutant animals, the highest values of proteogly-
can undersulfation are observed at birth, while sulfation increases with age.
Proteoglycans obtained from the femoral diaphysis of mutant animals are
slightly undersulfated and, as already observed in cartilage, there is an increase
in sulfation with age (P, 0.05 at P7 and P14; at the other age point, differ-
ences were not statistically significant). Bone sulfation analysis in mutant
animals at age P1 has not been possible, because of the reduced amount of
bone available (n.d., not determined). Sulfation of skin proteoglycans in
mutant animals is within normal values at all age points considered. Bars
represent the average values with the standard deviation (n ¼ 4) for wild-
type and mutant animals.
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validating the model. RNA studies indicated that the neomycin
gene in intron 2 interfered with splicing of the allele carrying
the point mutation. Therefore, the pathogenesis of the
chondrodysplasia phenotype in this strain comprises both the
structural amino acid change and reduced levels of correct-
sized, albeit mutation carrying, Dtdst mRNA caused by the
splicing impairment. In spite of this observation, the model
was not rejected because (i) most individuals affected by
one of the DTDST dysplasias are not homozygote, but rather
compound heterozygote for two of the many different known
mutations, and compound heterozygosity for a null allele and a
structural allele is frequent; (ii) all functional studies, in parti-
cular the sulfate uptake assay, confirmed the central role of
sulfate transport inactivation in the pathogenesis of the
observed phenotypic changes. In addition, as the observed
phenotype was severe (50% mortality during the first 3
weeks), this mouse strain could provide new data concerning
the role of proteoglycan sulfation during post-natal develop-
ment of the skeleton. Thus, we proceeded with an in-depth
characterization of the homozygous mutant mice during
post-natal development from birth to P60.
Considering the species differences between humans and
mice, the morphologic features of human DTD are well rep-
resented in the mutant mouse strain; in mutant animals, we
observed reduced growth, craniofacial abnormalities, kyphosis
and hip dysplasia. Phenotypic changes in mutant mice appear
very early: at birth, the whole skeleton is smaller than that in
wild-type littermates, and mutant pups show cartilage proteo-
glycan undersulfation and histological changes. Thus, the
phenotype originates in the fetal period, demonstrating that
the DTDST is functionally important in fetal development.
Indeed, human DTDST chondrodysplasias (with the exception
of the milder variant, rMED) can be diagnosed by ultrasound
in the fetal period (30).
Histological studies of cartilage tissue sections also demon-
strated similarities to human DTDST chondrodysplasia
patients. Cartilage stained less with toluidine blue, a cationic
dye with affinity to the sulfated, polyanionic proteoglycans.
H&E and toluidine staining showed normal growth plate
architecture at birth and during the first 3 weeks of age, but
disorganization of the growth plate was marked at P60,
explaining the postnatal component of growth failure.
TUNEL assay on the tibial growth plate at P21 showed few
apoptotic chondrocytes in the hypertrophic zone of mutant
animals when compared with the wild-types. Chondrocyte
apoptosis in endochondral ossification is a normal event
linked to the progression of chondrocytes towards a terminally
differentiated stage characterized by cell death and the for-
mation of lacunae, followed by vascular invasion and bone
formation (31). Reduced cell death in the hypertrophic zone
of mutant animals might be linked to a delay in the differen-
tiation process of chondrocytes. These data, together with
the finding of reduced chondrocyte proliferation in vitro,
suggest that reduced bone growth in DTDST disorders might
be due to reduced chondrocyte proliferation and/or incomplete
differentiation.
The finding of a delayed formation of the secondary ossifi-
cation center is at discrepancy with the notion of accelerated
bone maturation in human DTD patient; it is true though
that definitive fusion of the epiphysis to the metaphysis
approached in an early stage (P60) in the mutant mouse. Alka-
line phosphatase staining of osteoblasts in primary culture
from mutant mice was normal (data not shown) excluding a
severe osteoblastic functional defect. Even if subtle osteo-
blast/osteoclast defects cannot be excluded, the osteopenic
phenotype might be an indirect effect of abnormal cartilage
matrix rather than an osteoblast defect. The issue of bone
maturation thus remains to be determined with growth
kinetic studies of epiphyseal growth cartilage.
We did not observe changes in the external ears similar to
cystic swelling observed in DTD newborns, but this may be
due to the fact that mouse ears are formed by soft fibrous
tissue rather than by cartilage.
In cartilage of DTDST patients, the main biochemical con-
sequence of reduced intracellular sulfate availability is proteo-
glycan undersulfation (23). For this reason, we measured
cartilage proteoglycan sulfation in the femoral head cartilage
of mutant mice. Chondroitin sulfate proteoglycans were
undersulfated when compared with wild-type littermates (as
is observed in human DTD), but interestingly, there was a pro-
gressive increase in proteoglycan sulfation with age (P1–P60).
In DTDST disorders, the restriction of tissue alterations to
cartilage has been linked to the high amount of proteoglycans
synthesized by chondrocytes and thus to the ensuing high
sulfate requirements. Previous studies performed in fibroblasts
from DTDST patients demonstrated that the degree of proteo-
glycan sulfation depends also on the rate of proteoglycan
synthesis: proteoglycan undersulfation was dramatically high
when GAGs synthesis was enhanced by b-xylosides (23). As
the intracellular sulfate pool is limited due to a reduced
sulfate uptake per time unit, its depletion depends on proteo-
glycan synthesis rate and on proteoglycan species. Thus, the
tendency to more normal proteoglycan sulfation observed in
mutant mice over time may be explained by slower rate of
proteoglycan synthesis in older mice. An additional factor
that may affect proteoglycan sulfation comes from the forma-
tion of the secondary ossification center, which can provide
sulfate and other sulfur compounds through the blood
vessels penetrating the epiphyses and through the degradation
of cartilage matrix with lysosomal catabolism of GAG chains
(32,33).
A third factor modulating proteoglycan sulfation is intra-
cellular sulfate recruitment from the oxidation of thiols (e.g.
cysteine and methionine), which is significant in fibroblasts
and chondrocytes from DTDST patients (24,34). We do not
know to which extent this pathway is active in vivo, but the
presence of blood vessels in the second ossification center
may allow for sulfate recruitment from thiols.
The lack of any phenotype in skin (normal proteoglycan
sulfation) is in agreement with the amount and type of proteo-
glycans present in this tissue when compared with cartilage.
The amount of proteoglycans synthesized in skin is lower
compared with cartilage, and in addition, versican and the
small proteoglycans decorin and biglycan present in skin
bears considerably less GAG chains compared with cartilage
macromolecules (35). Thus, in fibroblasts, the intracellular
sulfate pool remains adequate to allow for sulfation of skin
proteoglycans.
Although the improvement in cartilage proteoglycan sulfa-
tion with aging, the histological and clinical data demonstrate
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that the development of skeletal abnormalities is progressive,
suggesting that other factors or sulfation of other macromole-
cules are involved in the pathogenesis of DTDST disorders. One
possible explanation is that degenerative changes in cartilage
are cumulative, and a late, partial recovery in proteoglycan
sulfation may not be enough to restore tissue trophism.
Another possible pathogenic mechanism for the progression
of skeletal changes may involve heparan sulfate proteogly-
cans; these macromolecules are relevant for efficient FGFs
signaling, which is crucial for the regulation of chondrocyte
proliferation and differentiation (36). Moreover, they affect
expression of other growth factors (i.e. Ihh) involved in endo-
chondral bone formation (37). Several lines of evidence
demonstrate that sulfation at specific positions along the
GAG chains play crucial roles in the formation of biologically
active domain structures independently from the overall level
of sulfation (38). Sulfation of heparan sulfate proteoglycans
has never been studied in DTDST disorders; however, it is
likely that modulating the overall sulfation status and/or the
sulfation at specific positions along the GAG chains will influ-
ence the availability of critical ligands and the optimal presen-
tation of signaling molecules to their receptors.
Keratan sulfate GAGs are an additional family of sulfated
oligosaccharide, which have so far not been studied in
DTDST chondrodysplasias. Lumican and keratocan, the
main keratan sulfate proteoglycans in the cornea, bear long,
highly sulfated keratan sulfate chains. Interestingly, in the
other tissues, these proteins occur as poorly sulfated or non-
sulfated glycoproteins (39). Thus, even if visual impairment
is not a feature of DTDST dysplasias, biochemical and ultra-
structural analyses of the cornea in mutant animals would be
worth of analysis. This hypothesis is further supported by
the observation that macular corneal dystrophy, an autosomal
recessive disorder with progressive punctate opacities in the
cornea, is caused by mutations in the N-acetylglucosamine-
6-sulphotransferase (CHST6 ) gene (40) leading to cornea
keratan sulfate undersulfation (41).
To gain new insight into the function and properties of
proteoglycans, several mouse strains have been generated in
which specific sulfotransferases have been knocked-out (38).
The mouse strain we have generated, together with the bm
mouse, are the only ones with a defect in the sulfation
pathway causing generalized undersulfation. Interestingly,
although the biochemical consequences of the defect are the
same (i.e. proteoglycan undersulfation), the two mouse
strains show several differences. The bm phenotype is
caused by a G79R substitution in PAPS synthase 2, which
activates sulfate to PAPS, the universal sulfate donor for
macromolecular sulfation; the mutation causes a partial loss
of function of the enzyme leading to reduced PAPS level
(27). Bm mice are normal in size at birth and the differences
become apparent during the first 4 weeks of life, suggesting
that the PAPS synthase 2 mutation specifically affects post-
natal skeletal development and other PAPS synthases may
be active and/or substitute PAPS synthase 2 during fetal devel-
opment (27). In bm mice at P25, proteoglycans from rib carti-
lage were more undersulfated (.50% non-sulfated
disaccaride) (28) than in our dtd mice. Taking into account
the severity of proteoglycan undersulfation observed in carti-
lage from patients with DTDST disorders (23) and from the
dtd mice, the bm phenotype should be more severe than
observed. This suggests that other factors besides macromol-
ecular sulfation affect the development and maintenance of
the skeletal elements. Thus, it can be predicted that the identi-
fication of additional components of the sulfation pathway, of
the proteoglycan metabolism and of the signaling pathways
involved in the expression of extracellular matrix proteins,
cytokines, growth factors and receptors in these animal
models will provide new insight in protein sulfation and ident-
ify new pathogenetic mechanisms in inherited and/or acquired
skeletal diseases.
In this study, we have generated a mouse strain with a
partial loss of function of the Dtdst causing a non-lethal chon-
drodysplasia phenotype; the biochemical, histological and
morphological studies validate this strain as a useful animal
model of DTD to explore pathogenetic and therapeutic
aspects of DTDST disorders. The non-lethal phenotype
allows to study the influence of proteoglycan undersulfation
on skeleton growth and maintenance, and therefore to trace
the progression of the DTD phenotype. In addition, tissue-
specific expression and sulfation of proteoglycans suggest
that other tissues, not accessible in humans, might be altered
(e.g. the cornea). No pharmacological treatment of DTD has
been available so far; the demonstration that cysteine-
derived compounds can increase the intracellular sulfate
pool in chondrocytes suggests that pharmacological treatments
might be tried to increase proteoglycan sulfation in the
patients (34). No data are available in vivo concerning the
contribution of this alternative pathway of sulfate recruitment
to the sulfate pool and the effective dose required to increase
proteoglycan sulfation in cartilage. The answers might be pro-
vided by the animal model before treatment of DTD patients
might be considered.
MATERIALS AND METHODS
Molecular cloning of the Dtdst gene and construction of the
gene targeting vector
To obtain the Dtdst gene, a 129Sv/J mouse BAC library
(Genome System Inc.) was screened by PCR using sense
and antisense primers corresponding to exon 2 (50-AAAGAG-
CAGCATGACCTCTC-30 and 50-TTCAGGTCATATTTTGG
GAGC-30) and to exon 3 (50-TGGGCTTTGTCTCTG
TCTACC-30 and 50-CGTGTAGCCATGTTTCTTGGC-30).
Primers were designed according to the cDNA sequence avail-
able at Genbank (Accession no. D42049). Two clones were
identified and were used to determine a restriction map of the
DTDST locus by Southern analysis using two probes for
exons 2 and 3, respectively. HindIII was found to cut the
gene into two fragments of 5.2 and 3.2 Kb suitable for the
gene-targeting vector. For subcloning of the two fragments,
BAC clones were digested with HindIII and restriction digests
analyzed by agarose gel electrophoresis. The regions on the
agarose gel corresponding to 5 and 3 kb were cut, and DNA
fragments in the agarose slices were subcloned in pBluescript
II (Stratagene). Clones were then screened to find the ones con-
taining the 5.2 and 3.2 kb inserts of the Dtdst gene. Once ident-
ified, the clones were sequenced to exclude recombination
errors during subcloning and the DNA sequence was compared
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to the same region on BAC clones. The C.T transition causing
the A386V substitution in the Dtdst was introduced in the clone
with the 3.2 Kb fragment by site-directed mutagenesis (GeneE-
ditor, Promega). The 5.2 Kb Dtdst fragment and, after site-
directed mutagenesis, the 3.2 Kb insert were then cloned in
the gene targeting vector which was constructed from a basic
targeting vector containing the thymidine kinase and neo
genes for negative selection and positive selection, respectively
(pKO Scrambler NTKV, Stratagene). The original vector was
modified flanking the neo gene by loxP sequences for possible
excision of the neo cassette by Cre recombinase after homolo-
gous recombination.
Generation of targeted embryonic stem cells and mice
Electroporation of the linearized targeting vector into AB1 ES
cells (kindly provided by Dr Alan Bradley, Baylor College,
Houston TX, USA) was followed by exposure to the neomycin
analogue G418 and ganciclovir. Survived colonies were iso-
lated and screened by Southern blot analysis for the recombi-
nant allele. Correct 50 targeting was checked by DNA
digestion with BstX I and membrane hybridization with a
BamH I fragment 614 bp long spanning 455 nucleotides
upstream the first codon to nucleotide 402 of the Dtdst
cDNA, whereas correct 30 targeting by digestion with Bsu36
I and hybridization with a 273 bp PCR fragment spanning
nucleotides 2195–2467. Numbering of nucleotides is accord-
ing to the cDNA sequence available at Genbank (accession no.
D42049). Targeted embryonic stem cells were injected in
BDF1  C57Bl/6J mouse blastocysts, according to standard
procedures (42). The resulting chimeric male mice were
mated with C57Bl/6J females to yield heterozygous animals.
Tail DNA was tested for the presence of the targeted allele,
using the same strategy described for embryonic stem cell
screening.
Northern blot analysis
Total RNA was extracted from skin of newborn animals
with Tri-Reagent (Sigma), according to the manufacturer’s
protocol. Approximately 250 mg of total RNA were used for
purification of mRNA using oligo(dT)-biotin and streptavidin
magnetic beads (mRNA Isolation Kit, Roche). Four micro-
grams of poly(A)þ RNAs were separated by gel electrophor-
esis in 1.2% formaldehyde–agarose denaturing gel and
blotted onto a nylon membrane (Hybond-Nþ, Amersham
Biosciences). Hybridizations with ULTRAHyb (Ambion) or
Rapid-hyb (Amersham Biosciences) were performed using a
273 bp PCR fragment spanning nucleotides 2195–2467 of
the Dtdst or a glyceraldehyde 3-phosphate deydrogenase
probe for the housekeeping gene; both probes were radio-
labeled with [32P]dCTP using Ready-to-Go DNA labeling
beads (Amersham Biosciences).
Skeletal preparations and histochemistry
Skeletal preparations of mice ranging from P1 to P21 were
made with an alcian blue–alizarin red method (43). Briefly,
pups were skinned, dehydrated in 96% ethanol, defatted in
acetone and stained with alcian blue and alizarin red.
Muscles were then removed with 1% KOH; preparations
were then stored in glycerol.
For histochemical studies, the whole limbs of animals were
fixed with 10% formaldehyde in phosphate buffer saline and
processed for light microscopy, according to standard pro-
cedure. Five micrometer sections were stained with H&E or
with toluidine blue. For detection of apoptotic cells by fluore-
scence microscopy in tibia growth plate sections, a TUNEL
assay (DeadEnd Fluorometric TUNEL System, Promega) was
used, according to the manufacturer’s instructions. Nuclei
were counterstained with 40,6-diamidino-2-phenylindole
(DAPI).
Cell cultures and sulfate uptake assays
Chondrocyte and skin fibroblast cultures were established
from pups at P1, whereas osteoblast cultures from pups at
P60. Skin fibroblasts were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal calf serum (FCS)
and antibiotics at 378C in 5% CO2. Chondrocytes were
released from epiphyseal cartilage by digestion with 1 mg/ml
collagenase A (Roche) in DMEM at 378C overnight. Dis-
sociated cells were washed with DMEM containing 10%
FCS and plated in the same medium. To recover osteoblasts,
the femoral diaphyses after bone marrow flushing were
finely minced and digested with 1 mg/ml collagenase A in
10 ml DMEM/Ham’s F-12K (1:1) at 378C for 2 h. Bone frag-
ments were then washed with DMEM/Ham’s F-12K (1:1),
seeded in Petri dishes and incubated in DMEM/Ham’s
F-12K (1:1) supplemented with 25 mg/ml ascorbic acid and
10% FCS. The osteoblastic phenotype was demonstrated by
alkaline phosphatase activity (44).
For chondrocyte proliferation assay, primary cultured cells
were grown on Lab-Tek Chamber Slides (Nunc) for 2 days
at 378C in 5% CO2 in DMEM supplemented with 10% inacti-
vated FCS and labeled in the same medium with BrdU for
4 h. At the end of the labeling period, detection of labeled
cells was performed, according to the manufacturer’s sugges-
tions using the 5-bromo-2-deoxyuridine labeling and detection
kit I (Roche). Cells were counterstained with DAPI. Percen-
tage of cells incorporating BrdU was determined by counting
positives on a total of 300 random nuclei in three independent
experiments.
For sulfate uptake assays, the same protocol was used for
either chondrocytes or osteoblasts in primary culture and for
skin fibroblasts at passage 4. Cells were seeded in 10 cm2
Petri dishes (3  105 cells per dish) and incubated in
DMEM (DMEM/Ham’s F-12K 1:1 for osteoblasts) containing
10% FCS for 24 h at 378C. Sulfate uptake was performed as
described previously using low ionic strength buffer (1 mM
MgCl2, 300 mM sucrose, 10 mM Tris–HEPES, pH 7.5) con-
taining concentrations of Na2SO4 ranging from 2 to 250 mM.
In preparation for the assay, cells were washed three times
with pre-warmed sulfate-free low ionic strength buffer and
pre-incubated for 2 min in the same buffer at 378C. Cells
were then incubated for 1 min at 378C in low ionic strength
buffer containing different concentrations of Na2SO4 and a
constant concentration (0.1 mM, corresponding to 150 mCi/ml)
of carrier-free Na2[
35S]O4 (PerkinElmer Life Sciences).
Following incubation, the uptake medium was removed and
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cells were washed four times with 1.5 ml of ice-cold medium
containing 100 mM sucrose, 100 mM NaNO3, 1 mM MgCl2
and 10 mM Tris–HEPES, pH 7.5. Cells were then lysed in
2% SDS and assayed for radioactivity and protein content.
Chondroitin sulfate disaccharide analysis
Disaccharide analysis was performed in skin, cartilage and
bone. Skin was carefully excised and freed from subcutaneous
fat. Cartilage was obtained from the femoral heads of pups at
P1–P60 by careful dissection under the microscope. In pups at
P1 and P7, femoral heads were cartilagineous, and in pups
at P14 and P21, the secondary ossification center was removed
with a tapered scalpel; whereas in pups at P60, the whole car-
tilage cup was removed from the bony part of the femoral head
by forcing with a blade. Bone was obtained from the diaphysis
of the femora after careful removal of the periosteum and of
bone marrow by flushing with phosphate buffer saline.
To recover GAGs, tissue specimens were digested with 10 U
of papain (Sigma) in 0.1 M sodium acetate, pH 5.6, 5 mM
EDTA and 5 mM cysteine at 658C for 48 h with further
supplementation of the same amount of papain after 24 h. For
decalcification of bone samples, the digestion buffer contained
100 mM EDTA. After papain inactivation at 1008C, released
GAGs were recovered by precipitation with 1% cetylpyri-
dinium chloride. The precipitate was washed three times with
10% potassium acetate in 96% ethanol and with 96% ethanol,
respectively. The precipitate was dried and solubilized in
hyaluronidase buffer (20 mM sodium acetate, pH 6.0, 75 mM
NaCl). Hyaluronic acid was removed by digestion with 4 U
of Streptomyces hyaluronidase (Seikagaku Corp.) at 608C over-
night followed by ultrafiltration with Ultrafree2 0.5 Centri-
fugal filter units (Millipore). Purified GAGs were digested
with 30 mU of both chondroitinase ABC and ACII (Seikagaku
Corp.) in 30 mM sodium acetate, 30 mM Tris–acetate, pH 7.35,
at 378C overnight. Undigested products were removed by pre-
cipitation with four volumes of ethanol and storage at 2208C
overnight (25,45). Supernatants containing disaccharides were
evaporated and solubilized in water. Disaccharides were fractio-
nated with a Supelcosil LC-SAX1 (Supelco) HPLC column
(4.6  250 mm2) using a gradient of 5–400 mM KH2PO4, pH
4.5, at room temperature, and the elution profile was measured
at 232 nm (23).
Statistical analysis
Two-way analysis of variance was used to determine differ-
ences among groups. Tukey’s test was used for multiple
comparison; differences in chondrocyte proliferation were
evaluated using Student’s t-test. A P-value ,0.05 was con-
sidered statistically significant.
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